At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 100 enrolled
Drug / intervention
Quercetin +1 moredrug
Likely dose
Quercetin 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Étude randomisée contrôlée Par Placebo de Phase II Visant à Mesurer l'Effet Anti-inflammatoire et Anti-sénescence de la quercétine Lors d'Une Chirurgie Cardiaque
In Brief
A Phase 2 clinical trial evaluating Quercetin and Placebo for Coronary Artery Disease. Completed, enrolled 100 participants across 1 site.
Detailed Summary
The purpose of this study is to test the anti-inflammatory and anti-senescence effects of quercetin during coronary artery by-pass graft surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartJun 2021
Primary CompletionDec 2023
Study CompletionMay 2025
TodayJul 2026
First PostedMay 28, 2021
Enrollment StartJun 4, 2021
Primary CompletionDec 1, 2023
Study CompletionMay 16, 2025
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.1 years ago
Interventions
Quercetindrug
500 mg twice daily
Placebodrug
twice daily